Download Substance P: A Neuropeptide

Images in Neuroscience
Carol A. Tamminga, M.D., Editor
Substance P: A Neuropeptide
cc
A
CO
Elevated CSF Substance P in PTSD
and depression is reported by
Geracioti et al., p. 637.
CPu
LS
PAG
VDB
VDB
B
DM
AcbC
AcbSh
RN
on
VP
VTA
Tu
200 µm
IpN
MG
DG
DG
SNR
200 µm
Immunofluorescence micrograph A shows substance P staining of a coronal section of mouse forebrain (light areas indicate presence of substance P). A moderately strong immunofluorescence is seen in the caudate nucleus (CPu), with the arrowheads pointing out uneven distribution
with more strongly stained "patches" (striosomes). In the lateral septum (LS), immunoreactivity is seen forming "baskets" (shown by arrow) surrounding septal neurons. Note the very strong immunoreactivity in the shell of the nucleus accumbens (AcbSh) versus a lower intensity in the
core (AcbC). There is a strong immunoreactivity in the ventral pallidum (VP). In contrast, the vertical limb of the diagonal band nucleus (VDB)
and cortical areas (CO) have only weak immunoreactivity. Immunofluorescence micrograph B shows substance P staining of a coronal section of
mouse ventral mesencephalon. Note very strong staining in the substantia nigra, in particular in its reticular part (SNR). This fluorescence extends dorsalaterally into the peripeduncular nucleus and the region around the medial geniculate nucleus (MG). There is a strong immunoreactivity in the lateral parts (arrow) of the interpeduncular nucleus (IpN), in contrast to the low substance P levels in its more central aspects. There
is strong staining in the central periaqueductal grey (PAG)-aqueduct indicated by the "asterisk"-and in the granular cell layer in the dentate gyrus
(DG) of the hippocampal formation (three yellow arrows). Cell bodies in the polymorph layer of the DG are substance P-positive (orange arrows).
Other abbreviations: cc=corpus callosum; DM=deep mesencephalic nucleus; on=optic nerve; RN=red nucleus; Tu=olfactory tubercle.
S
ubstance P is an 11-amino acid peptide belonging to the tachykinin family; it is widely distributed throughout the nervous
system of human and animal species. Peptides are synthesized
through translation and transcription, different from the classsic
neurotransmitters. Substance P is synthesized from a large precursor protein in the endoplasmic reticulum then transferred to
the Golgi apparatus for packaging and finally transported to the
cell membrane for exocytotic release. After synthesis, post-translational processing modifies the peptide structure. Substance P is
normally present at relatively high concentrations in nerve endings in selected regions of the mammalian brain, hence it is functionally available. Peptides almost always coexist with classic
transmitters, suggesting that their actions are complementary to
these classic transmitters. For example, substance P co-exists
with serotonin, thyrotropin-releasing hormone, and probably
glutamate in some bulbo-spinal neurons. In man, substance P
co-exists with serotonin in many dorsal raphe neurons projecting
to wide spread forebrain areas as well as with GABA and dynorphin in the striatal medium spiny neurons. Neurons may thus release a “cocktail” of messengers (peptides and classical transmitters) when stimulated to produce a spectrum of actions. In this
regard, classical transmitters and peptides differ in their mode of
synthesis and replacement after release. Transmitters are synthesized in nerve terminals and are taken back up into the presynap-
tic nerve ending after release; peptides are synthesized from DNA
in the cell body, transported to the synapse, and, once released,
metabolized, requiring new synthesis and axonal transport for
further action. Substance P is present in dorsal root ganglion (primary sensory) neurons and has been functionally linked to pain.
However, research into specific physiological roles for neuropeptides, including substance P, has remained elusive after several
decades of research, but transmitter-like, trophic, and modulatory actions are seen for most peptides. It is interesting that levels
of substance P (and other peptides) can change dramatically in
response to traumatic environmental events, and it is thought
that increases or decreases in peptide release, and in neuronal
sensitivity to peptides, can help neural systems adapt to trauma,
enhance survival, and promote recovery. Scientists have speculated that peptides exert their main actions when the nervous system is challenged or stressed, suggesting involvement with diseases of the brain and their availability as targets for therapeutic
intervention. In fact, an antidepressant action of a substance P
antagonist (NK1) was reported in 1998, but this effect could not
be confirmed in subsequent trials.
TOMAS HOKFELT
EUGENIA KUTEEVA
Stockholm, Sweden
Address reprint requests to Dr. Tamminga, UT Southwestern Medical Center, Department of Psychiatry, 5323 Harry Hines Blvd., #NC5.914, Dallas,
TX 75390-9070; [email protected] (e-mail).
578
ajp.psychiatryonline.org
Am J Psychiatry 163:4, April 2006